The short survival of patients with “double-hit” NDMM involving p53 (Walker et al., 2018a) and the prognostic value of sub-clonal p53 copy numbers (Shah et al., 2018) underline the clinical relevance of p53 as a target of and contributor to genomic instability in myeloma. The gene discussed is TP53; the disease is plasma cell myeloma.